Xenetic Biosciences, Inc.

General ticker "XBIO" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $5.5M (TTM average)

Xenetic Biosciences, Inc. follows the US Stock Market performance with the rate: 12.8%.

Estimated limits based on current volatility of 4.4%: low 2.37$, high 2.59$

Factors to consider:

  • Total employees count: 2 as of 2024
  • Top business risk factors: Lack of profitability, Operational and conduct risks, Early stage company risks, Economic downturns and volatility, Drug development risks
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [2.78$, 6.23$]
  • 2025-12-31 to 2026-12-31 estimated range: [2.72$, 6.10$]

Financial Metrics affecting the XBIO estimates:

  • Positive: with PPE of -1.6 at the end of fiscal year the price was low
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -44.39 <= 0.33
  • Negative: negative Industry operating cash flow (median)
  • Positive: Investing cash flow per share per price, % of 0 > -0.66
  • Positive: Shareholder equity ratio, % of 87.04 > 63.39
  • Negative: negative Net income

Similar symbols

Short-term XBIO quotes

Long-term XBIO plot with estimates

Financial data

YTD 2023-12-31 2024-12-31
Operating Revenue $2.54MM $2.50MM
Operating Expenses $7.06MM $6.70MM
Operating Income $-4.52MM $-4.20MM
Non-Operating Income $0.38MM $0.24MM
R&D Expense $3.49MM $3.29MM
Income(Loss) $-4.13MM $-3.96MM
Profit(Loss)* $-4.13MM $-3.96MM
Stockholders Equity $9.80MM $6.01MM
Assets $10.61MM $6.90MM
Operating Cash Flow $-4.11MM $-2.82MM
Capital expenditure $0.00MM $0.00MM
Earnings Per Share** $-2.71 $-2.57

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.